Coagulation deficiencies: A look to the future

Haemophilia

Volumn 12, Issue 5, 2006, Pages 531-540

  Aledort, L M ^a   Lee, C A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMG 531; B 1LN 2061; B7 ANTIGEN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; ELTROMBOPAG; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; MYC PROTEIN; PEGINTERFERON; PLACEBO; PRION PROTEIN; PROTEIN MDM2; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOPOIETIN; REMIPLISTIM; RIBAVIRIN; SCH 503034; SERINE PROTEINASE INHIBITOR; THROMBOPOIETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VX 950;

B LYMPHOCYTE ACTIVATION; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CARDIOTOXICITY; CELL MATURATION; CLINICAL TRIAL; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; GENE THERAPY; HEADACHE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA B; HEPATITIS C; HOMEOSTASIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER DYSFUNCTION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; THROMBIN TIME;

EID: 33747154108     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01324.x     Document Type: Conference Paper

References (55)

1. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-8.
2. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
3. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758-65.
4. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A 2004; 101: 14210-5.
5. Ansong C, Miles SM, Fay PJ. Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: Residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12. J Thromb Haemost 2006; 4: 842-7.
6. 2+ binding site required for cofactor activity. J Biol Chem 2004; 279: 12677-84.
7. 2+ binding site enhances cofactor interactions in factor Xase. Biochemistry 2005; 44: 10298-304.
8. Jenkins PV, Freas J, Schmidt K, Zhou Q, Fay PJ. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood 2002; 100: 501-8.
9. Jenkins PV, Dill J, Zhou Q, Fay PJ. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry 2004; 43: 5094-101.
10. Alpan O. Oral tolerance and gut-oriented immune response to dietary proteins. Curr Allergy Asthma Rep 2001; 6: 572-7.
11. Alpan O, Rudomen G, Matzinger P. The role of dendritic cells, B cells, and M cells in gut-oriented immune responses. J Immunol 2001; 166: 4843-52.
12. Lindsay M, Gil GC, Cadiz A, Velander WH, Zhang C, Van Cott KE. Purification of recombinant DNA-derived factor IX produced in transgenic pig milk and fractionation of active and inactive subpopulations. J Chromatogr A 2004; 1026: 149-57.
13. Van Cott KE, Monahan PE, Nichols TC, Velander WH. Haemophilic factors produced by transgenic livestock: Abundance that can enable alternative therapies worldwide. Haemophilia 2004; 10 (Suppl. 4): 70-6.
14. Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt-Jakob disease by blood products. Br J Haematol 2006; 132: 13-24.
15. Hilton DA, Ghani AC, Conyers L et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 20: 733-9.
16. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83: 2897-905.
17. Llewelyn CA, Hewitt PE, Knight RS et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
18. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
19. Head MW, Ironside JW. Mad cows and monkey business: The end of vCJD? Lancet 2005; 365: 730-1.
20. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 (Suppl. 3): S166-70.
21. Wen FQ, Jabbar AA, Chen YX et al. C-myc proto-oncogene expression in hemophilic synovitis: In vitro studies of the effects of iron and ceramide. Blood 2002; 100: 912-6.
22. Hakobyan N, Kazarian T, Jabbar AA et al. Pathobiology of hemophilic synovitis I: Overexpression of mdm2 oncogene. Blood 2004; 104: 2060-4.
23. Valentino LA, Hakobyan N, Kazarian T et al. Experimental haemophilic synovitis: Rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004; 10: 280-7.
24. Hakobyan N, Kazarian T, Valentino LA. Synovitis in a murine model of human factor VIII deficiency. Haemophilia 2005; 11: 227-32.
25. Manco-Johnson MJ, Pettersson H, Bradley CS et al. Physical therapy and imaging outcomes in a haemophilic population treated with factor prophylaxis: Current status and future directions. Haemophilia 2004; 10 (Suppl. 4): 88-93.
26. Nuss R, Kilcoyne RF, Geraghty S et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6: 162-9.
27. Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004; 10: 383-9.
28. Doria AS, Lundin B, Kilcoyne RF et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: Expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia 2005; 11: 245-53.
29. Lundin B, Ljung R, Pettersson H. MRI scores of ankle joints in children with haemophilia - comparison with clinical data. Haemophilia 2005; 11: 116-22.
30. Lundin B, Babyn P, Doria AS et al. The International Prophylaxis Study Group: Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11: 109-15.
31. Zeuzem S. The American Association for the Study of Liver Diseases: New perspectives in the treatment of hepatitis C. Antivir Ther 2006; 11: 267-71.
32. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
33. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-7.
34. Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia 2006; 12: 19-27.
35. Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102: 2412-9.
36. Manno CS, Chew AJ, Hutchison S et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-72.
37. Arruda V, Stedman H, Schuettrumpf J et al. A novel method of regional intravenous delivery of AAV vector in skeletal muscle results in correction of canine haemophilia B phenotype. Blood 2004; 104: 868a.
38. Nathwani AC, Davidoff AM, Hanawa H et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002; 100: 1662-9.
39. Manno CS, Arruda VR, Pierce GF et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-7.
40. Feese MD, Tamada T, Kato Y et al. Structure of the receptor-binding domain antibody fragment of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A 2004; 101: 1816-21.
41. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994; 91: 11104-8.
42. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132: 364-8.
43. Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002; 30: 1044-50.
44. Goodnough LT, Kuter DJ, McCullough J et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001; 98: 1346-51.
45. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-8.
46. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76: 628-38.
47. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
48. He S, Blomback M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-9.
49. Lisman T, Bijsterveld NR, Adelmeijer J et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1: 2368-73.
50. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: Effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95: 1694-702.
51. Barrowcliffe TW, Cattaneo M, Podda GM et al. New approaches for measuring coagulation. Haemophilia 2006; 12: 76-81.
52. Varadi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004; 10: 17-21.
53. Savidge G, Blomback M, Blomback B. Studies of F VIII procoagulant activity in plasma and concentrates using a semi-automated thrombin generation assay. Thromb Res 1979; 16: 355-65.
54. Varadi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
55. Turecek PL, Varadi K, Keil B et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay [Evaluation Studies]. Pathophysiol Haemost Thromb 2003; 33: 16-22.